SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending as traders discuss its potential within the privacy coin sector, drawing comparisons to ZEC and XMR. Community members are speculating on possible catalysts for a price surge, with some suggesting a potential move towards $100 or higher. Discussions also involve DASH's technical setup, supply dynamics, and its possible integrations or partnerships.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss the company's recent record-high monthly deliveries, which increased significantly year-over-year, and potential impacts from upcoming economic and trade-related events. The community highlights the delivery numbers as a sign of growth and a possible turning point, while also considering the competitive landscape and broader market factors. Anticipation is building for continued growth and the potential for a profitable quarter.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN Crypto is trending as community members discuss its potential following its migration to Base, with some anticipating a breakout similar to ZCash. Conversations also highlight ZEN's strong fundamentals and the possibility of Grayscale launching a trust, further fueling interest. The token's potential for privacy-focused DeFi applications is also being discussed.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential, hindered by low trading volume and debates over its marketing and tokenomics. Recent developments like Caffeine AI are generating both excitement and skepticism, with some seeing it as a game-changer and others questioning its real-world impact. Overall, conversations revolve around whether ICP can deliver on its technological promise and achieve mainstream adoption.

D.R. Horton, Inc. engages in the construction and sale of single-family housing. It operates through the following geographical segments: Northwest, Southwest, South Central, Southeast, East, and North. The Northwest segment relates to Colorado, Oregon, Utah, and Washington. The Southwest segment covers Arizona, California, Hawaii, Nevada, and New Mexico. The South Central segment is involved in Arkansas, Oklahoma, and Texas. The Southeast segment refers to Alabama, Florida, Louisiana, and Mississippi. The East segment operates Georgia, North Carolina, South Carolina, and Tennessee. The North segment focuses on Delaware, Illinois, Indiana, Iowa, Kentucky, Maryland, Minnesota, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia. The company was founded by Donald Ray Horton in 1978 and is headquartered in Arlington, TX.

D.R. Horton Inc.

DHI is trending due to recent earnings and outlook, coupled with shifting sentiment on the housing market. While some analysts express concern over affordability and potential market saturation, others point to the company's strong fundamentals and strategic positioning. Community discussions revolve around whether DHI can maintain its performance amid broader economic uncertainties.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Mind Medicine Inc - Ordinary Shares (Sub Voting)

MNMD is trending as investors discuss its chart patterns, potential buyouts (Pfizer mentioned), and the overall bullish sentiment in the psychedelic therapeutics industry following positive news from competitors like Cybin. Community members highlight key technical formations and long-term growth potential, while also speculating about potential FDA vouchers and partnerships. The discussion is also around the Phase 3 trial results expected in H1 2026.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler ($ZS) is trending as traders discuss its strong bullish setup, particularly a cup and handle pattern, with some anticipating a breakout and a move towards $400. Bullish sentiment is further fueled by analyst upgrades and a focus on long-term compounding growth within the zero-trust architecture cybersecurity space. However, some traders express caution, citing concerns about earnings expectations and potential pullbacks.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its potential, emphasizing its steady floor and readiness for a breakout. Bulls are expressing conviction, particularly with the anticipation of a broader crypto market rally possibly influenced by macro factors. Community members are closely watching key levels and expressing confidence with the $WAGMI hashtag.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the first US ETF tracking Litecoin launched, though some traders are expressing concern over low initial trading volume.  Community members are debating whether the ETF approval was already priced in, while others are anticipating a significant price increase as institutional investors enter the market. Bullish sentiment remains around Litecoin's long-term potential and its digital silver narrative.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid speculation about its potential role in privacy-focused integrations, possibly linked to Elon Musk's X platform, sparking community discussion about its use case versus competitors. Some community members are drawing comparisons to Bitcoin's early days, while others highlight its privacy features as a key differentiator in the crypto landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Metsera Issues Statement in Response to Litigation

Metsera Issues Statement in Response to Litigation Metsera Issues Statement in Response to Litigation PR Newswire NEW YORK, Oct. 31, 2025 NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc...

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Amazon & Apple Lift Sentiment, Nvidia Hopes to Sell China Blackwell Chips  The Opening Trade 10/31

US stock futures advanced after strong earnings from Amazon and Apple. Amazon surged 12% in premarket trading on its fastest cloud-unit growth in nearly three years, while Apple gained on a revenue...

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Equity

Mizuho's Holtz talks what is behind Novo's bid for Metsera

Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat...

Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to...

<ul class="summary-bullets"><li>Novo Nordisk announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September.</li><li>Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients.</li><li>The company is now looking to enter the booming obesity market with an acquisition. &nbsp;</li></ul>Retail investors on Stocktwits expect Pfizer to make an acquisition bid for Metsera’s rival, Viking Therapeutics, as the company’s agreed-upon deal with Metsera hangs in limbo.Danish drugmaker Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-submits-revised-bid-for-metsera-enters-bidding-war-with-pfizer/cLGFsgdR3x2">announced</a> on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera has now given Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.&nbsp;“The best part would be if PFE lets NVO walk away with MTSR rather than up its own bid a few billion dollars, and instead makes a better offer to VKTX,” a Stocktwits user wrote.<stembedurl>https://stocktwits.com/spodero/message/634314721</stembedurl>Another sees Viking ending up with a good deal in time.<stembedurl>https://stocktwits.com/Idvst8/message/634311871</stembedurl>Shares of VKTX traded 10% higher at the time of writing. On Stocktwits, retail sentiment around VKTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients. The company is now looking to enter the booming obesity market with an acquisition.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking, meanwhile, is evaluating both subcutaneous and oral formulations of its obesity program VK2735 in clinical trials. It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.In early and mid-stage trials, subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 4% this year and approximately 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera 

Viking and Metsera are both attempting to develop drugs for the treatment of obesity.

<ul class="summary-bullets"><li>Novo has proposed to acquire all outstanding shares of Metsera’s common stock at a price of $56.50 per share in cash and additional milestone payments of up to $21.25 per share.</li><li>Pfizer on Thursday lashed out at the proposal, terming it “reckless,” “unprecedented,” and “illusory.”</li><li>Metsera declared that the Novo Nordisk proposal is “superior” and it may negotiate potential adjustments to the existing Pfizer transaction in light of the new proposal. &nbsp;</li></ul>Danish drugmaker Novo Nordisk (NVO) said on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR) after Pfizer (PFE) agreed to acquire the smaller obesity biopharmaceutical company in September.New York City-based Metsera is developing medicines for obesity and cardiometabolic diseases. Novo has <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916443">proposed</a> to acquire all outstanding shares of Metsera’s common stock at a price of $56.50 per share in cash and contingent value rights (CVRs) for up to $21.25 per share in cash, which will be received on the achievement of certain milestones.The company also said that the cash consideration would be paid at signing in exchange for non-voting preferred stock representing 50% of Metsera’s share capital. The CVRs will be issued upon the closing of the acquisition in exchange for the remaining shares, it added.<h2 class="st-heading-2">Pfizer-Metsera Deal</h2>Pfizer had said in September that it would acquire Metsera for $47.50 per share in cash at closing, and contingent value rights (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones.Novo is now proposing to buy Metsera for as much as $77.75 per share, compared to Pfizer’s maximum bid value of $70 per share.<h2 class="st-heading-2">Pfizer Hits Back</h2>Pfizer on Thursday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251030787900/en/Pfizer-Addresses-Proposal-for-Metsera"> lashed</a> out at the proposal, terming it “reckless,” “unprecedented,” and “illusory.”“It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger,” Pfizer said. “The proposal is illusory and cannot qualify as a superior proposal under Pfizer’s agreement with Metsera, and Pfizer is prepared to pursue all legal avenues to enforce its rights under its agreement,” it added.According to Pfizer, Metsera previously rejected Novo Nordisk’s proposal due to “a variety of risks” in its deal structure.<h2 class="st-heading-2">Metsera Responds</h2>Metsera on Thursday <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.metsera.com/news-releases/news-release-details/metsera-receives-unsolicited-proposal-novo-nordisk">declared</a> that the Novo Nordisk proposal is “superior,” and it may negotiate potential adjustments to the existing Pfizer transaction in light of the new offer.Pfizer has the right to negotiate adjustments for four business days from Thursday’s notice, it noted.While Pfizer holds that it does not believe Metsera has the right to deliver this notice, Metsera said that it disagrees. Metsera would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal, it said.“At this time, the Pfizer Merger Agreement remains in full effect, and Metsera's Board of Directors reaffirm their recommendation that the holders of Metsera common stock approve the adoption of the Pfizer Merger Agreement and approve the Merger with Pfizer on the terms and subject to the conditions set forth in the Pfizer Merger Agreement,” the company said.However, Semafor <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid">reported</a> on Thursday afternoon, citing a person familiar with the matter, that Pfizer is preparing to sue Metsera and also possibly Novo Nordisk.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/MTSR">MTSR shares</a> traded 20% higher in the pre-market session at the time of writing, while <a href="https://stocktwits.com/symbol/NVO">NVO shares</a> slumped 2%. On Stocktwits, retail sentiment around MTSR jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘high’ levels.MTSR stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-amid-mixed-big-tech-earnings/cLGFrZmR3DC">Dow Futures Decline Amid Mixed Big Tech Earnings: META, MSFT, GOOGL, AAPL Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor’s Note: The story has been updated with information from a recent report about Pfizer’s potential legal action against Metsera and Novo Nordisk.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer

Novo is now proposing to buy Metsera for as much as $77.75 per share, compared to Pfizer’s maximum bid value of $70 per share.

Metsera Receives Unsolicited Proposal from Novo Nordisk

Metsera Receives Unsolicited Proposal from Novo Nordisk Metsera Receives Unsolicited Proposal from Novo Nordisk PR Newswire NEW YORK, Oct. 30, 2025 Metsera Declares Novo Nordisk Proposal 'Superior...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.72	--	--	N/A
Q2 '25	-$0.66	-$0.66	-0.29%	MISSED
Q1 '25	-$0.94	-$1.03	-8.99%	MISSED
Q4 '24	-$0.61	-$3.52	-477.05%	MISSED

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest MTSR News

MTSRMetsera Inc